Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.64 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.64 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | ERN1 | O75460 | 3/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.43 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | CCND1 | P24385 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicyladehyde SCHEMBL10708393 | 0.85 | TRIM24 (0.82) | TRIM24TRIM33CA2CA1ERN1 | |
| Salicyladehyde SCHEMBL1980238 | 0.83 | TRIM24 (0.78) | TRIM24TRIM33CA2CA1ERN1 | |
| Salicyladehyde SCHEMBL28421628 | 0.81 | TRIM24 (0.82) | TRIM24TRIM33CA2CA1ERN1 | |
| Salicyladehyde SCHEMBL10454896 | 0.80 | TRIM24 (0.90) | TRIM24TRIM33CA2CA1ERN1 | |
| Salicyladehyde SCHEMBL27610933 | 0.80 | TRIM24 (0.90) | TRIM24TRIM33CA2CA1ERN1 | |
| Salicyladehyde SCHEMBL29386538 | 0.80 | — | — | |
| Salicyladehyde SCHEMBL15395 | 0.80 | — | — | |
| Salicyladehyde SCHEMBL901265 | 0.80 | TRIM24 (1.00) | TRIM24TRIM33CA2CA1ERN1 | |
| Salicyladehyde SCHEMBL4055035 | 0.79 | TRIM24 (0.78) | TRIM24TRIM33CA2CA1ERN1 | |
| Salicyladehyde SCHEMBL6229738 | 0.79 | TRIM24 (0.78) | TRIM24TRIM33CA2CA1ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9925153-B2 | Therapeutic agents for skin diseases and conditions | STC.UNM (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160287531-A1 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | STC.UNM | 2016-10-06 | — | — | US | disclosed |
| WO-2015085143-A2 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | STC.UNM (US) | 2015-06-11 | — | — | WO | disclosed |
| US-8980954-B2 | Substituted cis- and trans-stilbenes as therapeutic agents | STC.UNM (US) | 2015-03-17 | — | — | US | disclosed |
| US-8524782-B2 | Key intermediate for the preparation of Stilbenes, solid forms of Pterostilbene, and methods for making the same | LAURUS LABS PRIVATE LIMITED (IN) | 2013-09-03 | — | — | US | disclosed |
| US-20130178536-A1 | SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS | STC.UNM (US) | 2013-07-11 | — | — | US | disclosed |
| US-20110144212-A1 | KEY INTERMEDIATE FOR THE PREPARATION OF STILBENES, SOLID FORMS OF PTEROSTILBENE, AND METHODS FOR MAKING THE SAME | APTUIT LAURUS PRIVATE LIMITED (IN) | 2011-06-16 | — | — | US | disclosed |
| WO-2010010578-A2 | A KEY INTERMEDIATE FOR THE PREPARATION OF STILBENES | APTUIT LAURUS PRIVATE LIMITED (IN) | 2010-01-28 | — | — | WO | disclosed |
| US-20070249647-A1 | Substituted CIS- and trans-stilbenes as therapeutic agents | REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287531-A1 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | CUTA, TSLP, ELANE | TRIM24 3780/4885TRIM33 967/4885CA2 2954/4885 |
| US-20070249647-A1 | Substituted CIS- and trans-stilbenes as therapeutic agents | TGFB1, VHL, TMSB10 | TRIM24 3519/4885TRIM33 2507/4885CA2 3656/4885 |
| US-20130178536-A1 | SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS | PSEN1, TERT, PSEN2 | TRIM24 2985/4885TRIM33 1844/4885CA2 3242/4885 |
| US-20110144212-A1 | KEY INTERMEDIATE FOR THE PREPARATION OF STILBENES, SOLID FORMS OF PTEROSTILBENE, AND METHODS FOR MAKING THE SAME | SIRT5, SQLE, PDHB | TRIM24 2618/4885TRIM33 653/4885CA2 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.